To conduct a pragmatic, randomized controlled trial to assess whether thiopurine methyltransferase (TPMT) genotyping prior to azathioprine reduces adverse drug reactions (ADRs). Methods: A total of 333 participants were randomized 1:1 to undergo TPMT genotyping prior to azathioprine or to commence treatment without genotyping. Results: There was no difference in the primary outcome of stopping azathioprine due to an adverse reaction (ADR, p = 0.59) between the two study arms. ADRs were more common in older patients (p = 0.01). There was no increase in stopping azathioprine due to ADRs in TPMT heterozygotes compared with wild-type individuals. The single individual with TPMT variant homozygosity experienced severe neutropenia. Conclusion: Our work supports the strong evidence that individuals with TPMT variant homozygosity are at high risk of severe neutropenia, whereas TPMT heterozygotes are not at increased risk of ADRs at standard doses of azathioprine.
A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study Adoption of pharmacogenetic tests into clini cal practice has been limited for a number of reasons [1] , including a lack of robust evidence and the need for randomized controlled trials (RCT) to demonstrate clinical utility [2] .
Azathioprine is a thiopurine immuno suppressant widely used for the treatment of a range of inflammatory disorders, including inflammatory bowel disease. Its use is limited by a range of common side effects, including nau sea, vomiting and rashes, which leads to discon tinuation of therapy in up to a third of patients [3] . Bone marrow suppression and especially neutropenia, is an important adverse reaction (ADR) [4] . Individuals deficient in thiopurine methyltransferase (TPMT), an important rate limiting enzyme in the conversion of azathioprine to its active metabolite, 6thioguanine nucleotide (6TGN), are at high risk of earlyonset profound neutropenia [5, 6] . Approximately one in 300 indi viduals have a complete deficiency of this enzyme activity [5, 7] . In the majority of cases, across all eth nic groups, enzyme deficiency can be accounted for by carriage of two copies of the common variant alleles termed TPMT*2, TPMT*3A and TPMT*3A [8] . A number of case reports [9, 10] and retrospective series [6, [11] [12] [13] of patients treated with azathioprine supported an association between low TPMT activity and profound, earlyonset neutro penia. This led to recommendations for the adop tion of either genetic or enzyme testing prior to azathioprine use to reduce the incidence of neutro penia [14] , relabeling of the drug package insert in the USA, advice in the British National Formulary and the approval of a diagnostic test by the US FDA in 2004 [15] . However, testing for TPMT status has limitations in that it does not predict all individuals at risk of thiopurineinduced neutro penia [11] and only has a weak association with the other side effects associated with this medication. In addition, 10% of individuals have intermedi ate TPMT activity [5, 7] , due to heterozygosity for a deficient allele. This reduces enzyme activity by 50% and reports have emerged regarding both the increased rate of ADRs in this group [16, 17] and a potential increase in drug efficacy due to increased conversion to 6TGNs [18] . Adoption of clinical TPMT testing by 2005 in the UK was relatively sparse [19] and clinical practice guidelines did not recommend clinicians to use it. Notably, the British Society of Gastroenterologists stated: "It [TPMT testing] cannot yet be recommended as a prerequisite to therapy, because decades of experience has shown clinical aza(thioprine) to be safe in ulcerative colitis or Crohn's disease" [20] .
Importantly, no large RCT has established the clinical utility of TPMT testing. Therefore, we designed and undertook a pragmatic RCT, aiming to reflect reallife clinical practice in patients with a range of inflammatory diseases, to determine if TPMT genotyping could reduce the incidence of ADRs.
Methods & patients n Design overview
This was a pragmatic RCT (ISRCTN30748308) to establish if the use of TPMT genotyping would reduce ADRs associated with azathio prine. The study was approved by the ethical review committee (05/MRE12/5) and each patient provided written informed consent. (Supplementary  table 2) . Patients were excluded if they had pre viously stopped azathioprine because of pan creatitis or severe neutropenia (neutrophil count <1 × 10 9 /l), had a current neutrophil count of <1 × 10 9 /l, impaired liver function (alanine transaminase > twice the upper limit of normal), or impaired renal function (glomerular filtration rate <20 ml/min) at baseline. Patients who were pregnant or breastfeeding, had a hypersensitiv ity to azathioprine, or who had previously had TPMT enzyme testing were also excluded. Patients with a coprescription of allopurinol were excluded due to the increased risk of thiopurine toxicity through xanthine oxidase inhibition. The first patient was recruited on 18/10/2005 and the final recruit on 31/12/2007. n Randomization & interventions Study patients were randomized 1:1 to receive standard care based on individual clinician prac tice with routine hematological and biochemical monitoring (nongenotyping arm) or to undergo TPMT genotyping.
Blood samples were collected from all patients at recruitment. Following trial entry and base line assessment, patients were allocated ran domly to the genotyping or nongenotyping arms on receipt of the pretreatment blood sample at the genetics laboratory and the treating clinician being informed. Randomization was stratified by study center and speciality, using computer generated lists with a variable blocksize prepared by the study statistician. The laboratory staff had no knowledge of patient status except for name, date of birth and referring clinician and had no involvement with patient recruitment or treat ment. Individuals allocated to the genotyping arm had TPMT genetic testing undertaken. Results were generated within 1 week and the referring clinician was informed of the result prior to the commencement of azathioprine. In the nongenotyping arm, the blood sample was stored and TPMT genotyping was undertaken at completion of the study. Study clinicians were not blinded to the status of the participants, as the study was reliant on the study physician pre scribing azathioprine in light of the TPMT test result in the genotyped arm.
Genotyping for individ uals with a wildtype TPMT genotype, they were advised to start a mainte nance dose of azathioprine (i.e., 1.5-3 mg/kg/ day); for individuals with a heterozygous TPMT genotype, they were advised to start azathioprine at a low dose (i.e., 25-50 mg/day) and titrate to the maintenance dose; for individuals homozygous for TPMT variant alleles, they were advised not to start azathioprine, but to use an alternative treat ment. However, all final treatment decisions were at the discretion of the treating clinicians. Phenotype was determined by measuring red blood cell TPMT activity measurements using a modified version of the liquid chroma tographyfluorescence assay [21] . Briefly, TPMT metabolism of the substrate 6thioguanine was quantified by measuring the rate of formation of the fluorescence metabolite 6methylthi oguanine, expressed relative to red blood cell lysate hemoglobin content.
n Outcomes & follow-up Baseline clinical data were collected at enrol ment. Standardized outcome data were collected at 4 months from multiple sources including case notes, patient diaries and case report forms. Case note review was undertaken at 12 months on all patients still taking azathioprine at 4 months to establish later onset ADRs. ADRs were reported by patients, treating physician and verified by the trial manager, using laboratory test results, where appropriate. Laboratory monitoring tests, including full blood counts and liver function tests, were undertaken according to local guid ance. Hepatotoxicity was defined as alanine transaminase ≥two times upper limit of normal range; neutropenia (severe <1.0 × 10 9 /l and mod erate 1.0-1.5 × 10 9 /l) and pancreatitis as serum amylase ≥two times upper limit of normal range.
In addition, at 4month review, a blood sam ple was assayed for TPMT activity and the aza thioprine metabolites, 6TGNs and 6methyl mercaptopurines. Metabolites were assayed using an adapted liquid chromatography-UV assay [22] . In the Crohn's disease patients, the Harvey-Bradshaw index (HBI) was used to assess disease activity at recruitment and at 4 months followup [23] .
n Statistical analysis Analyses were conducted on an intentiontotreat basis. The primary end point was initially defined as severe hematological ADRs that required the dose of azathioprine to be reduced, or the treat ment stopped, in the first 4 months of therapy. The study was designed to have 80% power, (twosided 5% significance level) to detect a change in the incidence of the primary end point from 14 to 8%, based on the available literature at the time [24] . This required 500 patients in each arm. A preplanned, blinded, interim review of event rates in the first 100 patients established that rates of neutropenia were considerably lower than initially predicted (1.3%). A revised pri mary end point was agreed by the independent steering committee and defined as stopping aza thioprine due to any ADR in the first 4 months of treatment. This was based on evidence that individuals with reduced TPMT activity were at increased risk of ADRs requiring treatment cessation [30] . The study was resized to have 80% power to detect a 40% reduction in stop ping azathioprine due to occurrence of an ADR (the revised primary end point -a composite of the original primary and a secondary end point) with a total of 330 patients. Predefined secondary end points included moderate neutropenia (neu trophil count 1-1.5 × 10 9 /l) in the first 4 months of azathioprine treatment, and drug efficacy. The odds ratios (ORs) for overall ADR rates were estimated with mixed logistic regression models adjusting for specialty and age as fixed effects and center as a random effect as prespecified. As the number of events for individual ADRs was small, these were compared using unadjusted Fisher's exact tests. Dose levels were compared between trial arms and genotypes using Mann-Whitney U tests.
Results
The trial profile is illustrated in Figure 1 . In total, 336 subjects were recruited, of whom three were excluded (duplicate sample, age <16 years, copre scription of allopurinol). The baseline charac teristics of the study patients are summarized in table 1. The demographic profiles and baseline clinical characteristics of the genotyping and nongenotyping arms were similar. There were no differences in TPMT variant genotype fre quencies between the two study arms. The over all TPMT variant genotype frequencies were one homozygote in 333 individuals [0.3, 95% con fidence interval [CI]: 0.02-1.7 and 34 heterozy gotes [10.2, 95% CI: 7.4-13.9], similar to those reported previously in the UK [7] . No rare TPMT variant alleles were identified in any patient by a screen of all previously reported TPMT variants. As the trial was pragmatic in nature, we were not prescriptive about the type or frequency of blood monitoring in the two study arms. We observed a modest, but nonsignificant, excess of blood draws (including full blood count, electrolytes and liver function tests) in the nongenotyping arm of 6.7 versus 5.8 mean blood draws in the genotyping arm (p = 0.26, Mann-Whitney U test).
n TPMT genotyping does not reduce azathioprine-related ADRs At 4 months, of the 333 eligible individu als recruited 322 had provided outcome data (Figure 1 ). Of the 322 individuals, 91(28.3%) patients had stopped azathioprine due to an ADR. In addition, four individuals had died, none due to azathioprinerelated toxicity (Supplementary table 3) ; five had stopped due to inefficacy and 13 had never started azathioprine. With regard to the primary end point, there was a trend to stopping azathioprine with increasing age due to ADRs (OR: 1.3; 95% CI: 1.1-1.5 per decade; p = 0.01) (Supplementary Figure 1) , but there was no significant association between special ity (OR: 0.49; 95% CI: 0.20-1.2; p = 0.12) or gender (OR: 0.98; 95% CI: 0.60-1.6; p = 0.95) and the number of ADRs within 4 months.
There was no difference in the frequency of stopping azathioprine due to an ADR at 4 months in the two study arms (genotyping 47/163 In total, 116 out of 322 (36.0%) patients expe rienced one or more ADR in the first 4 months of followup. Hepatotoxicity was more common in the genotyping arm, although this difference would not be considered significant after allow ing for the number of ADRs tested, and the numbers are small, so such comparisons have limited statistical power. The one individual in the nongenotyped arm who was homozygous for TPMT variant alleles experienced severe, early onset nonfatal neutropenia after azathioprine treatment. Two other cases of moderate neutro penia (1-1.5 × 10 9 /l) occurred in patients with wildtype TPMT in the genotyped arm. These patients had no defined cause for neutropenia, which occurred at 75 and 91 days, respectively. Case note review was undertaken at 12 months in the 181 patients who were still taking azathioprine at 4 months. Six cases of moderate neutropenia were recorded. Of these, one individual was a TPMT heterozygote and the others were TPMT wildtype. No obvious precipitants for the neutropenia were recorded and there were no striking differences in the concomitant medications in the two study arms n Effect of TPMT genotyping on the starting & maintenance dose of azathioprine The trial was pragmatic in design and the only intervention was the TPMT genotype result and associated advice regarding appropriate azathio prine prescription. Therefore, we attempted to establish whether TPMT genotyping altered prescribing practice. In the nongenotyping arm, when clinicians did not have the patients' TPMT status, the average starting dose was similar between patients wildtype or heterozygous for TPMT variants (table 3) . In the genotyping arm, when the TPMT status was available, the average starting dose of azathioprine was lower in the TPMT heterozygotes than wildtype individu als (p = 0.007). This indicated that, overall, the clinicians were initiating treatment at a lower dose for TPMT heterozygotes as advised by the genotype result. However, the average starting dose in the TPMT wildtype individuals was similar in the two arms (table 3) . At 4 months, the mean azathioprine dose across both arms was 1.68 mg/kg/day. There was no difference in dose at 4 months between the two study arms (p = 0.25) or between individuals heterozygous or wildtype for variant TPMT alleles (p = 0.98). Furthermore, the prescribing dose patterns of azathioprine between initiation and at 4 months were not different between the two arms.
n TPMT genotyping does not improve azathioprine efficacy At baseline, there was no difference in HBI scores between the Crohn's disease patients in the two arms. The mean HBI of >5 in both study arms at recruitment indicated active dis ease [23] . At 4 months, despite only twothirds of patients continuing with azathioprine, there was a modest improvement in clinical symp toms in both the study arms (mean HBI of <5), with no significant differences between the arms (table 4) . At baseline, 52 out of 113 CD patients had a HBI of <5, whereas at 4 months of aza thioprine treatment, 75 out of 112 CD patients had a HBI <5 (p = 0.002) n TPMT genotype-phenotype correlations All individuals heterozygous or homozygous for TPMT variant alleles had either intermediate or negligible TPMT enzyme activity, respectively. All individuals wildtype for the three tested TPMT variant alleles had normal/high TPMT activity, except for two with borderline inter mediate levels. DNA sequencing of the entire TPMT open reading frame did not detect a vari ation in these two individuals that would explain their lower enzyme levels (Figure 2) .
In 13 (3.9%) of the patients, there had been a blood transfusion in the 3 months prior to recruit ment to the study (Supplementary table 6) . There was no discordance between the TPMT genotype and enzyme activity in these individuals. 6thioguanine nucleotide and 6methylmer captopurines metabolite levels at 4 months indi cated that eight out of 129 (6%) patients, who were still recorded as on azathioprine and on whom samples were available for ana lysis, had absent metabolite levels and may therefore have been nonadherent with treatment.
Discussion
We present the findings of the first large rand omized controlled pharmacogenetics study con ducted to establish the clinical utility of TPMT testing prior to azathioprine dosing. Despite only one patient in this study being deficient for TPMT, consistent with retrospective series [11] and case reports of TPMT deficient patients [25-27], our trial reinforces that such individuals are at a significantly increased risk of azathioprine induced profound neutro penia and azathio prine should therefore be avoided or used very cautiously in this patient group [28] . However, contrary to other studies, our report provides no evidence to indicate that TPMT hetero zygotes (i.e., individuals with inter mediate enzyme activity) are at increased risk of neutropenia [16, 17, [29] [30] [31] [32] 33] . This difference may be explained by a later onset of neutropenia in TPMT hetero zygotes, beyond the 4month followup cutoff used in our study [12, 30] . However, ana lysis in the extended followup group did not indicate an association between TPMT heterozygosity and neutropenia. Likewise, our study does not indi cate that TPMT heterozygotes are at increased risk of stopping azathioprine due to ADRs, con trasting with a prospective study, which found that 79% of TPMT heterozygotes had stopped azathioprine at 6 months compared with 35% with wildtype TPMT [30] . Again, this differ ence, may in part, be explained by the differ ence in the length of study followup and the set dose of 2 mg/kg/day for all patients recruited to the previous study [ However, the basis upon which these recommen dations were made was from "evidence obtained from expert committee reports or opinions, and/ or clinical experience of respected authorities … [with] an absence of directly applicable studies of good quality" [36] . Therefore, there was a need for a trial to establish the role of TPMT testing. However, the increased uptake of TPMT test ing coincided with the conduct of this trial and severely impacted on recruitment, as some cent ers felt that allocation to not undertake TPMT testing would be against professional guidance. Our study is considerably larger than the two previous RCTs of 29 and 63 patients, which have considered TPMT testing prior to azathioprine treatment [37, 38] . Neither study was powered to establish the role of TPMT in predicting toxicity. The increased likelihood of ADRs in elderly patients has been well documented [39] . However, we believe our study is the first formal demon stration of this for azathioprine and indicates that clinicians should be especially vigilant in monitoring elderly patients on azathioprine.
Our study does not demonstrate any advan tage or disadvantage of TPMT genotyping com pared with phenotyping. However, importantly, nearly 4% of patients had a blood transfusion in the 3 months prior to recruitment. Patients defi cient in TPMT have been misclassified if they have had a recent transfusion due to the activity in the donor erythrocytes [40] . The tight corre lation between the two methods indicates that phenotyping, supplemented with geno typing in specific circumstances (e.g., after recent blood transfusion) is entirely appropriate [41] [42] [43] .
There is no published actual cost data that directly compare the resource use associated with TPMT genotyping, phenotyping or no testing when prescribing azathioprine and impact on subsequent treatment pathways. Existing cost data, used in economic model ling studies, are from estimates of resource use, using expert opinion, comparing testing with current practice [44] . Further research is required to establish the relative cost and outcomes of TPMT genotyping, phenotyping or no testing.
The pragmatic design of this study allowed us to assess physician practice in the interpre tation of TPMT genotype results. Physicians started TPMT heterozygotes on a lower dose of azathioprine, consistent with the guidance on the clinical report. However, overall they did not start known TPMT wildtype individuals on the recommended maintenance dose, but preferred to use a lower starting dose. Despite the fact that individuals with normal TPMT activity are at decreased risk of azathioprineinduced neutro penia, the implicit concern that TPMT testing does not predict other side effects, including nausea and myalgia, which commonly occur after treatment initiation and lead to intoler ance, means that introduction of TPMT testing will not lead to more rapid treatment induction.
Our study supports previous work that aza thioprine is an effective treatment in achiev ing or maintaining remission in the subset of patients with Crohn's disease by lowering of the mean HBI to <5 [3] . This improvement was achieved at an average maintenance dose of 1.68 mg/kg/day, similar to the effective dose achieved in a randomized study of azathioprine use in atopic eczema [29] and lower than the dose used in some previous studies [30] . Interestingly, we found no difference in the rates of remission achieved between the genotyped and nongeno typed arms and no evidence that TPMT het erozygotes achieved remission with lower doses of azathioprine.
In conclusion, previous reports indicate that pharmacogenetic testing for TPMT status is important to identify variant homozygote (~1/300) individuals who are at high risk of severe neutropenia with standard dose azathio prine treatment. This is supported by the severe neutropenia experienced by the single variant homozygote in our study. Unfortunately, our study was not adequately powered to formally establish this important relationship. However, 
Future perspective
Randomized controlled trials are considered the optimum way to generate robust data to inform clinical decisionmaking. To date, few prospective RCT studies have been conducted in pharmaco genetics, the study on HLA-B*5701 and abacavir is a notable successful exception [45] . However, retrospective pharmacogenetic analy ses are increasingly being undertaken on RCTs where the primary outcome was not related to pharmacogenetics, for example with clopi dogrel [46, 47] . Sometimes the adverse event is so rare or the strength of the association is so strong that undertaking an RCT would be unfeasible or inappropriate [34] . Despite the expense, time and effort, undertaking RCTs in pharmacoge netics can generate valuable information and pragmatic studies that assess utility in reallife clinical settings are especially relevant. 
